A Phase 3 interventional study of chlorothiazide and Rauwolfia alkaloids in Cardiovascular Diseases, Heart Diseases and Hypertension, sponsored by National Heart, Lung, and Blood Institute (NHLBI). Completed. Open to participants aged 21 Years to 55 Years. Per ClinicalTrials.gov, last updated 2013-11-26.
Sponsored by National Heart, Lung, and Blood Institute (NHLBI) · Phase 3, Interventional, and Prevention
To determine whether the long-term treatment of essential hypertension without significant target organ disease materially influenced mortality and/or cardiovascular renal morbidity.
BACKGROUND:
This grant-supported, cooperative, fixed-protocol clinical study was initiated in 1966 and followed a cooperative study of the treatment of renal hypertension initiated in 1960 to evaluate the relative efficacy of several recognized drug regimens for reduction of blood pressure. Six centers (USPHS hospitals) and a coordinating center were involved in the trial.
DESIGN NARRATIVE:
Randomized, double-blind, fixed sample. Three hundred and eighty nine eligible patients were assigned to drug therapy consisting of chlorothiazide plus Rauwolfia serpentina or to placebo.
The study completion date listed in this record was inferred from last publication listed in the Citations section of this study record.
6,689 studies on the registry are indexed under Hypertension; 965 are open to participants now.
Browse Hypertension studies →National Heart, Lung, and Blood Institute (NHLBI) is the lead sponsor of 1,117 studies on the registry; 71 are open to participants now.
Of its 57 completed or terminated interventional studies of FDA-regulated products, 49 (86%) have results posted.
Counted across the registry records on this site, refreshed daily.
Men and women, ages 21-55. Mild essential hypertension (diastolic blood pressure over 90 mm Hg.
No study locations are listed for this record.
This study is completed, as verified in Jan 2000. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Heart, Lung, and Blood Institute (NHLBI)